Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation Miniperspective

Hydrophobic tag-based protein degradation: Development, opportunity and challenge

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Hydrophobic Tag Tethering Degrader As a Promising Paradigm of Protein Degradation: Past, Present and Future Perspectives

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

Development of Novel Silicon-Based Hydrophobic Tags (SiHyT) for Targeted Proteins Degradation

Hydrophobic tagging of small molecules: an overview of the literature and future outlook

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Targeted protein degradation: mechanisms, strategies and application

Targeted protein degradation in drug development: Recent advances and future challenges

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

A novel hydrophobic tag leads to the efficient degradation of programmed death-ligand 1

Targeted Degradation of DNA/RNA Binding Proteins Via Covalent Hydrophobic Tagging

Advancing targeted protein degradation for metabolic diseases therapy

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Novel approaches to targeted protein degradation technologies in drug discovery

Recent advances in targeted protein degraders as potential therapeutic agents

Targeted protein degradation directly engaging lysosomes or proteasomes

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Beyond Canonical PROTAC: Biological Targeted Protein Degradation (Biotpd)